NASDAQ:OTIC - Otonomy Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Otonomy Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.20 -0.35 (-9.86 %) (As of 01/24/2020 03:01 PM ET) Add Compare Today's Range$3.20Now: $3.20▼$3.6050-Day Range$2.43MA: $3.14▼$4.0652-Week Range$1.94Now: $3.20▼$4.18Volume10,231 shsAverage Volume241,622 shsMarket Capitalization$98.40 millionP/E RatioN/ADividend YieldN/ABeta2.74 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC Previous Symbol CUSIPN/A CIK1493566 Webhttp://www.otonomy.com/ Phone619-323-2200Debt Debt-to-Equity Ratio0.60 Current Ratio6.66 Quick Ratio6.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$750,000.00 Price / Sales131.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book1.23Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-50,370,000.00 Net Margins-6,516.78% Return on Equity-72.06% Return on Assets-45.67%Miscellaneous Employees49 Outstanding Shares30,750,000Market Cap$98.40 million Next Earnings Date3/2/2020 (Estimated) OptionableOptionable Receive OTIC News and Ratings via Email Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OTIC Rates by TradingView Otonomy (NASDAQ:OTIC) Frequently Asked Questions What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." How were Otonomy's earnings last quarter? Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.12. The biopharmaceutical company earned $0.13 million during the quarter, compared to analyst estimates of $0.31 million. Otonomy had a negative net margin of 6,516.78% and a negative return on equity of 72.06%. View Otonomy's Earnings History. When is Otonomy's next earnings date? Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Otonomy. What price target have analysts set for OTIC? 4 brokers have issued twelve-month price targets for Otonomy's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate Otonomy's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price. View Analyst Price Targets for Otonomy. What is the consensus analysts' recommendation for Otonomy? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy. What are Wall Street analysts saying about Otonomy stock? Here are some recent quotes from research analysts about Otonomy stock: 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (1/7/2020) 2. HC Wainwright analysts commented, "Our $8 12-month target is based on a 60% probability of success adjusted DCF. We only include in our model—assuming 2022 launch and over $300M peak sales—and do not include any contribution from the early-stage pipeline. Our DCF reflects a 12% WACC discount rate and 1% terminal growth beyond 2028, which we think is appropriate assuming IP into the 2030s, and a likely high generic bioequivalence bar for locally acting therapy, requiring a head-to-head clinical trial." (8/29/2019) Has Otonomy been receiving favorable news coverage? News coverage about OTIC stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Otonomy earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Otonomy. Are investors shorting Otonomy? Otonomy saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 131,200 shares, an increase of 5.2% from the November 28th total of 124,700 shares. Based on an average daily volume of 99,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.5% of the shares of the company are short sold. View Otonomy's Current Options Chain. Who are some of Otonomy's key competitors? Some companies that are related to Otonomy include Xenon Pharmaceuticals (XENE), BioSpecifics Technologies (BSTC), Catalyst Pharmaceuticals (CPRX), Aptorum Group (APM), ProQR Therapeutics (PRQR), Fulcrum Therapeutics (FULC), DURECT (DRRX), Verrica Pharmaceuticals (VRCA), Avedro (AVDR), Progenics Pharmaceuticals (PGNX), AnaptysBio (ANAB), Lexicon Pharmaceuticals (LXRX), Merus (MRUS), AMAG Pharmaceuticals (AMAG) and Urovant Sciences (UROV). What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Corbus Pharmaceuticals (CRBP), Catabasis Pharmaceuticals (CATB), Melinta Therapeutics (MLNT), Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Strongbridge Biopharma (SBBP), Spectrum Pharmaceuticals (SPPI) and Marathon Oil (MRO). Who are Otonomy's key executives? Otonomy's management team includes the folowing people: Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)Dr. David Allen Weber, Pres, CEO & Director (Age 59)Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel How do I buy shares of Otonomy? Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $3.20. How big of a company is Otonomy? Otonomy has a market capitalization of $98.40 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy. What is Otonomy's official website? The official website for Otonomy is http://www.otonomy.com/. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected] MarketBeat Community Rating for Otonomy (NASDAQ OTIC)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 283 (Vote Underperform)Total Votes: 574MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Dividend Aristocrat Index
